Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This news was unfortunate in the short term, but hopefully will be countered by a positive outcome in the near future:
https://ir.tetrabiopharma.com/newsroom/press-releases/news-details/2021/Tetra-Bio-Pharma-Announces-Up-To-13.0-Million-Marketed-Public-Offering-of-Units/default.aspx
Tetra Bio-Pharma Announces Up To $13.0 Million Marketed Public Offering of Units
12/01/2021
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/
OTTAWA, ON, Dec. 1, 2021 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has entered into an agreement with Research Capital Corporation and Echelon Wealth Partners Inc., acting as co-lead agents and joint bookrunners (the "Agents"), in connection with a marketed public offering of units of the Company (the "Units") for aggregate gross proceeds of up to $13,000,000 (the "Offering"), at an indicative price of $0.18 per Unit, priced in the context of the market.
Each Unit will be comprised of one common share of the Company (a "Common Share") and one Common Share purchase warrant of the Company (a "Warrant"). Each Warrant will entitle the holder thereof to purchase one Common Share at an indicative exercise price of $0.25, priced in the context of the market, for a period of 48 months following the closing of the Offering.
The Company has granted the Agents an option (the "Over-Allotment Option") to increase the size of the Offering by up to an additional number of Units, and/or the components thereof, that in the aggregate would be equal to approximately 15% of the total number of Units to be issued under the Offering, to cover over-allotments, if any, and for market stabilization purposes, exercisable at any time and from time to time up to 30 days following the closing of the Offering.
The net proceeds from the Offering will be used by the Company for clinical trials, working capital and general corporate purposes.
The closing of the Offering is expected to occur on or about December 9, 2021 (the "Closing"), or on such date as agreed upon between the Company and the Agents, and is subject to the Company receiving all necessary regulatory approvals, including the approval of the Toronto Stock Exchange (the "Exchange") to list, on the date of Closing, the Common Shares and the Common Shares issuable upon exercise of the Warrants and compensation warrants thereon. In addition, the Company will use commercial reasonable efforts to obtain the necessary approvals to list the Warrants on the Exchange as soon as reasonably after the Closing.
In connection with the Offering, the Company intends to file a prospectus supplement (the "Supplement") to the Company's short form base shelf prospectus dated April 1, 2020 (the "Shelf Prospectus"), with the securities regulatory authorities in each of the provinces of Canada, except Quebec. Copies of the Shelf Prospectus and, the Supplement to be filed in connection with the Offering, can be found on SEDAR at www.sedar.com. The Shelf Prospectus contains, and the Supplement will contain, important detailed information about the Company and the Offering. Prospective investors should read the Supplement and accompanying Shelf Prospectus and the other documents the Company has filed on SEDAR at www.sedar.com before making an investment decision.
This press release is not an offer to sell or the solicitation of an offer to buy the securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from U.S. registration requirements and applicable U.S. state securities laws.
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1) is a leader in cannabinoid-derived drug discovery and development with a FDA and a Health Canada cleared clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. Their evidence-based scientific approach has enabled them to develop a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. With patients at the core of what they do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing biopharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
This news release contains certain statements which constitute forward-looking statements or information under applicable Canadian securities laws, including statements relating to the expected size of the Offering, the anticipated timing of closing the Offering, the ability of the Company to satisfy all conditions to closing the Offering, and the expected use of proceeds from the Offering. Such forward-looking statements are subject to numerous known and unknown risks, uncertainties and other factors, some of which are beyond the Company's control, which could cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. These risks and uncertainties include general economic and capital markets conditions, stock market volatility, the ability of the Company to obtain necessary consents for the Offering, including the approval of the Exchange, and the ability of the Company to complete the Offering on the terms expected or at all. Although the Company believes that the forward-looking statements in this news release are reasonable, they are based on factors and assumptions, based on currently available information, concerning future events, which may prove to be inaccurate. As such, readers are cautioned not to place undue reliance on the forward-looking statements, as no assurance can be provided as to future plans, operations, results, levels of activity or achievements. The forward-looking statements contained in this news release are made as of the date of this news release and, except as required by applicable law, the Company does not undertake any obligation to publicly update or to revise any of the forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE Tetra Bio-Pharma Inc.
They could only know when the request came from OTC after the review. OTC is slow and unpredictable, unfortunately.
Thanks. I got the same and I like this part of what he said:
"the new counsel sounds like he's got his act together...Past Counsel sounds like a "bad egg"
Having competent counsel is key to getting CE removed.
UNSS LONG and STRONG
For every Seller, there's a Buyer. It's not matter of going up or down, but a confirmation that shares were exchanged (traded) at an agreed strike price (PPS).
Thank you! :)
Market finally reacted at the end of day with volume and higher PPS but this nothing compared to what’s to come. AIMHO
HUGE NEWS today! Oh man, TBPMF is about to explode on the scene! Tetra Bio Pharma is a Multi billion dollar company in the making!!!
$TBPMF $TBP
*I believe he did secure a new legal counsel
I believe he has from what could tell. The previous one seemed like a pain in the B Lol
Haha thanks. It's the opposite, my goal is to world travel while trading penny stocks and UNSS is #1 on my list.
It's not even close Lol. I love this board. ;)
This sounds very promising!:
"Preliminary analysis of the data shows a positive effect on pain relief in QIXLEEFTM-treated patients"
My pleasure! I meant to share last week, but on Friday I started on a big adventure traveling to Paris-Malta-Thailand for the next 3-5 months, so was quite busy preparing before my flight!
It will easily run as well, and even better once CE is removed.
On that, Watkins mentioned last week that he got an update from Paul on what has been requested by OTC for CE removal. Paul/ Legal Counsel are on it.
Hopefully all gets done, shortly!
UNSS LONG AND STRONG
No reason it can’t get back to penny land when things pickup
Short term is unpredictable up or down, but if trials are positive, this will take off like a super rocket. I am Long.
I love loading in quiet-bottom times. Going for DRNK win #9 in last 2 years!
Market is not responding to all the good news and progress. This will change soon. Let's get those trial results out!
Great insight and feedback. I am not going anywhere and believe UNSS will see this trough, and that Watkins is willing to wait for all to be sorted out. I've been thinking the same, that this wait could be beneficial in the long term. Many of us Longs benefitted from the PPS drop in price to load up this summer...so I see the delays as a glass half full situation. One in which many of us could benefit greatly in the future and even make us millionaires. There's no guarantees but I'd say are chances are pretty darn good.
UNSS Long & Strong
GGRN which was became Pink limited around the same time as UNSS in July, just got its CE status removed today (almost 4 months later). I just think this will take a lot of patience but will eventually get there for UNSS, as well.
UNSS Long & Strong
Very nice news!:
https://www.ema.europa.eu/en/glossary/orphan-designation
Orphan designation
A status assigned to a medicine intended for use against a rare condition. The medicine must fulfil certain criteria for designation as an orphan medicine so that it can benefit from incentives such as protection from competition once on the market.
More info here:
https://www.ema.europa.eu/en/human-regulatory/overview/orphan-designation-overview
"About 30 million people living in the European Union (EU) suffer from a rare disease. The European Medicines Agency (EMA) plays a central role in facilitating the development and authorisation of medicines for rare diseases, which are termed 'orphan medicines' in the medical world."
New tweet!: We’re pleased to share we have received Orphan Drug Designation from the European Medicines Agency, for QIXLEEF™, as a potential treatment for Complex Regional Pain Syndrome, a chronic neuropathic pain condition. $TBP $TBPMF
We’re pleased to share we have received Orphan Drug Designation from the European Medicines Agency, for QIXLEEF™, as a potential treatment for Complex Regional Pain Syndrome, a chronic neuropathic pain condition. $TBP $TBPMF pic.twitter.com/04vTyDGW3A
— Tetra Bio-Pharma (@TetraBioPharma) November 16, 2021
"Late filing is not surprising. Since we did not see a filing in Sept, I assumed that there would be a late filing.
The questions I have now are:
1) do they have a new legal counsel working on this now?
2) What does If we are not able to secure legal opinion before committed filing date the disclosure will be filed mean?"
****
- Filings were due Nov. 15 (today), hence the Late filing notification. Now due Nov 20th.
- Yes to 1), as stated in Filing: "We have been forced to retain new legal counse"
- They mean they will file Q3 Fins by November 20 deadline, even if they don't have the information requested by OTC ready by then.
Hope this helps.
NOTIFICATION OF LATE FILING -
I was little quick in determining why the Filings are late. The Filings state:
"Reason for Delay in Posting Financial Report: State below in reasonable detail why the Annual/Quarterly Report could not be filed within the prescribed time period.
We are working to complete the response to OTC Markets regarding the Caveat Emptor. We have been forced to retain new legal counsel as a result of not being able to reach or receive credible updates and response from original counsel. If we are not able to secure legal opinion before committed filing date the disclosure will be filed."
It seems OTC have made some requests for UNSS to comply to in order to get CE removed. The delay is disappointing, but at least there seems to be a path forward.
https://www.otcmarkets.com/otcapi/company/financial-report/311443/content
UNSS LONG & STRONG
ASZP was first ticker to have CE removed in almost 2 months. Hopefully UNSS not far behind and Paul doesn't delay Q3 Fins, due today. They are as simple as can be!
UNSS Long & Strong
Glad you admit it.
UNSS LONG AND STRONG
Happy to share. Cheers!
Here's what Watkins had to say via email:
"Spent a good hour with Paul... we're on it... CE should be going soon... but out of our direct control.
Not sure there is really much more they can ask for... ie OTC..."
If he's optimistic, then I'm optimistic.
UNSS Long & Strong
Wow good to see they are catching up. UNSS HOPEFULLY NEXT!
I'm surprised there isn't that much excitement about the OTCQB news which will attract institutional investors. This is a big deal!
Miami, FL (November 9, 2021) — Organicell Regenerative Medicine, Inc. (OTCQB: OCEL), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that its application to uplist its common stock to the OTCQB Venture Market (the “OTCQB”) has been approved by OTC Markets Group, Inc. Organicell’s common stock will commence trading on the OTCQB under the symbol “OCEL” commencing at the opening of the market on November 9, 2021.
The OTCQB, operated by OTC Markets Group Inc., is designed for developing and entrepreneurial companies in the United States and abroad. To be listed on OTCQB, companies must be current in their financial reporting and undergo an annual verification and management certification process, including meeting a minimum bid price and other financial conditions. With more compliance and quality standards, the OTCQB provides investors improved visibility to enhance trading decisions. The OTCQB is recognized by the United States Securities and Exchange Commission as an established public market providing public information for analysis and value of securities and trading.
Albert Mitrani, CEO, commented, “our listing on the OTCQB is another important milestone for Organicell. It will provide us greater visibility within the investment community, which should increase our access to institutional and retail investors. This additional capital markets exposure will be valuable, as we expect to pursue capital raising opportunities to support our planned clinical trials in connection with the Company’s lead product, Zofin™”.
About Zofin™
Zofin™ is an acellular biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent. Zofin™ contains over 300 growth factors, cytokines, and chemokines as well as extracellular vesicles/nanoparticles.
ABOUT ORGANICELL REGENERATIVE MEDICINE, INC.
Organicell Regenerative Medicine, Inc. (OTCQB: OCEL) is a clinical-stage biopharmaceutical company that harnesses the power of exosomes to develop innovative biological therapeutics for the treatment of degenerative diseases. The Company’s proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring exosomes, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent. Based in South Florida, the company was founded by Albert Mitrani, Chief Executive Officer and Dr. Mari Mitrani, Chief Scientific Officer. To learn more, please visit https://organicell.com/.
FORWARD-LOOKING STATEMENTS
Certain of the statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended (the “Securities Act”), the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by the use of forward-looking terminology such as “will”, “believes”, “expects”, “potential”, or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. We remind you that actual results could vary dramatically as a result of known and unknown risks and uncertainties, including but not limited to: potential issues related to our financial condition, competition, the ability to retain key personnel, product safety, efficacy and acceptance, the commercial success of any new products or technologies, success of clinical programs, ability to retain key customers, our inability to expand sales and distribution channels, legislation or regulations affecting our operations including product pricing, reimbursement or access, the ability to protect our patents and other intellectual property both domestically and internationally, and other known and unknown risks and uncertainties, including the risk factors discussed in the Company’s periodic reports that are filed with the SEC and available on the SEC’s website (http://www.sec.gov). You are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Specific information included in this press release may change over time and may or may not be accurate after the date of the release. Organicell has no intention and specifically disclaims any duty to update the information in this press release.
Media Contact:
Joshua Rodriguez
Joshua@CNAFinance.com
(503) 464-6502
Huge news! Uplifting to OTCQB
Organicell announces its application to uplift its common stock to the OTCQB Venture Market (the “OTCQB”) has been approved by OTC Market Group, Inc. Effective November 9, 2021, common stock will commence trading on the OTCQB under the symbol $OCEL.
— Organicell (@organicellTM) November 9, 2021
https://t.co/Z285ewzTUm pic.twitter.com/crYNOuRBue
Oh wow, how’s it going? I wish you well!
I can confirm canadians can buy ;)
DB*MM was upgraded to otc pink current info about a month ago, AND still has a Caveat Emptor Buyer beware status, so it is possible.
That would be just amazing. I'm guessing Pink Current would be the first step, then their might be a waiting period for CE removal but just a matter of when, not if.
Quite a few tickers were upgraded to Pink Current from Pink Limited so far this week. UNSS could be next!
How would we know anything about your personal life?
To be clear, Darrell A. Calloway is no longer part of UNSS's management team.
Let's hope! :)